Lecap Asset Management Ltd. Lowers Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Lecap Asset Management Ltd. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,020 shares of the biopharmaceutical company’s stock after selling 3,030 shares during the quarter. Lecap Asset Management Ltd.’s holdings in Gilead Sciences were worth $926,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. HHM Wealth Advisors LLC raised its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth $25,000. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth $29,000. Finally, Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several research analyst reports. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Piper Sandler lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. UBS Group upped their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $87.00 to $113.00 in a research note on Friday, January 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 572,824 shares of company stock worth $53,611,715. 0.29% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

GILD stock opened at $96.04 on Friday. The firm has a 50-day moving average of $92.97 and a 200 day moving average of $86.49. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market cap of $119.69 billion, a P/E ratio of 1,067.11, a PEG ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.